Trial Profile
Sorafenib (NEXAVAR) monotherapy in patients with inoperable/recurrent germ cell carcinoma refractory to chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2010
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Testicular cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MRS
- 10 Sep 2010 New trial record